Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for Izicopan (C5aR Inhibitor) in Atypical Hemolytic Uremic Syndrome. The expected timing is based on the latest available company guidance and may change.
08/06/26:- aHUS open-label proof-of-concept data expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.